Working with an experienced nutrition coach will go a long way to maximize your GLP-1 diets results
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents In collaboration with Eli Lilly, we showed that the dual GLP-1/GIP agonist Tirzepatide robustly decreases preference for palatable foods by selectively decreasing lipid consumption
Once treatment starts, care is not episodic
This is especially useful for clinics, weight loss programs, and patients who need customized care
Users may view pharmacological weight loss as more legitimate or effective than other methods, reinforcing moral hierarchies around body management
For physically active users, they may subtly affect recovery, endurance, and performance over time